173 related articles for article (PubMed ID: 16411647)
1. [Reasons for the under-use of secondary prevention therapies in coronary patients over the age of 70 years].
Cournot M; Cambou JP; Quentzel S; Danchin N
Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S17-23. PubMed ID: 16411647
[TBL] [Abstract][Full Text] [Related]
2. Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: Results from the ELIAGE and ELICOEUR surveys.
Cournot M; Cambou JP; Quentzel S; Danchin N
Int J Cardiol; 2006 Jul; 111(1):12-8. PubMed ID: 16046011
[TBL] [Abstract][Full Text] [Related]
3. Secondary prevention of coronary heart disease in the elderly.
Dornbrook-Lavender KA; Roth MT; Pieper JA
Ann Pharmacother; 2003 Dec; 37(12):1867-76. PubMed ID: 14632542
[TBL] [Abstract][Full Text] [Related]
4. Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?
Fox DJ; Kibiro M; Eichhöfer J; Curzen NP
Postgrad Med J; 2005 Jun; 81(956):401-3. PubMed ID: 15937208
[TBL] [Abstract][Full Text] [Related]
5. Treatment with statins after acute myocardial infarction in patients >or=80 years: underuse despite general acceptance of drug therapy for secondary prevention.
Kvan E; Pettersen KI; Landmark K; Reikvam A;
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):261-7. PubMed ID: 16315337
[TBL] [Abstract][Full Text] [Related]
6. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
[TBL] [Abstract][Full Text] [Related]
7. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up.
Turley AJ; Roberts AP; Morley R; Thornley AR; Owens WA; de Belder MA
Interact Cardiovasc Thorac Surg; 2008 Apr; 7(2):231-4. PubMed ID: 18234766
[TBL] [Abstract][Full Text] [Related]
8. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Vermeer NS; Bajorek BV
J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
[TBL] [Abstract][Full Text] [Related]
9. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
[TBL] [Abstract][Full Text] [Related]
10. [Changes in the prescription of cardiovascular prevention drugs in France between 1995 and 2003: factors influencing the gap between evidence base medicine and clinical practice].
Philippe F; Cambou JP; Danchin N; Thomas D
Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S30-6. PubMed ID: 16411649
[TBL] [Abstract][Full Text] [Related]
11. [Management of the cardiology patient with polyvascular disease: PRISMA study].
Cournot M; Cambou JP; Ferrières J; Grenier O; Herrmann MA; Cantet C; Leizorovicz A
Arch Mal Coeur Vaiss; 2004 Sep; 97(9):841-8. PubMed ID: 15521475
[TBL] [Abstract][Full Text] [Related]
12. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the use of hypolipidemic agents (HAs), mainly statins, in elderly subjects aged 80 years and more in Burgundy: analysis of 13,211 patients.
Manckoundia P; Lorenzini M; Disson-Dautriche A; Petit JM; Lorcerie B; Debost E; Menu D; Pfitzenmeyer P
Arch Gerontol Geriatr; 2012; 55(1):101-5. PubMed ID: 21868109
[TBL] [Abstract][Full Text] [Related]
14. [Prognosis at six months for coronary patients: impact of antiplatelet agents and statins].
Ferrières J; Cambou JP; Cantet C; Guize L
Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S10-6. PubMed ID: 16411646
[TBL] [Abstract][Full Text] [Related]
15. An intervention to improve secondary prevention of coronary heart disease.
Bailey TC; Noirot LA; Blickensderfer A; Rachmiel E; Schaiff R; Kessels A; Braverman A; Goldberg A; Waterman B; Dunagan WC
Arch Intern Med; 2007 Mar; 167(6):586-90. PubMed ID: 17389290
[TBL] [Abstract][Full Text] [Related]
16. Quality of care for secondary prevention for patients with coronary heart disease: results of the Hastening the Effective Application of Research through Technology (HEART) trial.
Goff DC; Gu L; Cantley LK; Sheedy DJ; Cohen SJ
Am Heart J; 2003 Dec; 146(6):1045-51. PubMed ID: 14660997
[TBL] [Abstract][Full Text] [Related]
17. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.
Austin PC; Tu JV; Ko DT; Alter DA
CMAJ; 2008 Oct; 179(9):901-8. PubMed ID: 18936455
[TBL] [Abstract][Full Text] [Related]
19. [Health care quality: medication and prevention in patients with and without coronary heart disease].
Baberg HT; Yazar A; Brechmann T; Grewe P; Kugler J; De Zeeuw J; Bojara W; Lawo T; Mügge A
Med Klin (Munich); 2004 Jan; 99(1):1-6. PubMed ID: 14716479
[TBL] [Abstract][Full Text] [Related]
20. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
